X
<
1
Important Events that Could Drive Markets this Week

President Trump’s executive order on healthcare, the Iran nuclear agreement, and news about North Korea preparing for a launch ahead of US–South Korea military exercises failed to trigger higher volatility.

part-1-3-1
US Steel Had a Big Week: What Happened?

US steel stocks have had a tepid year after the spectacular rally last year, and there’s a sense of apprehension in the market that US steel prices could go lower.

Sector
S&P 500, NASDAQ, and Dow Closed Strong Last Week

The S&P 500 started last week on a weaker note. On October 13, the S&P 500 closed the day higher and ended the week with gains.

PCG-mkt-perf-1
Wildfires in California Set PG&E Ablaze, Stock Tumbles 7%

PG&E Corporation saw its stock fall ~7% on October 12—its steepest fall in seven years—on speculations that downed power lines caused wildfires in California.

RECENT Healthcare RESEARCH

graph_1
Mylan in 2017: What You Should Know

In 2Q17, Mylan reported revenues close to $3.0 billion, which is a YoY rise of around 16.0%, mainly driven by increased sales in Europe and the Rest of World markets.

Chart-01-Products-1
What Analysts Recommend for Sage Therapeutics

Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company focused on the development and commercialization of drugs for the treatment of central nervous system disorders.

life-sciences-strategy-1
Must-Know Investor Updates from Beckton Dickinson

Becton Dickinson accelerated its strategy to establish itself as the leader in single cell genomics with its recent launch of BD Rhapsody, a single cell analysis platform.

global-leader-1
Abbott Laboratories's Recent Landmark Development

On September 14, 2017, Abbott Laboratories (ABT) announced that its landmark clinical trial results show that the Amplatzer PFO Occluder device reduces the risk of ischemic stroke recurrence by 45.0%.

operational-efficiency-1
Baxter's Management Changes: Do They Mean Higher Growth Momentum?

Baxter International (BAX) has been going through a cost transformation and reorganization process for some time. The initiative includes some leadership and management changes.

Graph-1-2-1
Regeneron’s Outlook for 2017: Eylea, Kevzara, and Dupixent

Of the 26 analysts covering Regeneron Pharmaceuticals in September 2017, seven rated the stock a “strong buy,” six rated it as a “buy,” and 12 rated it as a “hold.” One analyst rated the company as a “strong sell.”

Analysts-Ratings-2-1
Who's Watching TEVA Now?

In August 2017, the FDA approved Teva Pharmaceutical’s (TEVA) Austedo for the treatment of adult individuals with tardive dyskinesia.

Chart-01-Rev-EPS-1
These Are Gilead Sciences’ Key Growth Drivers

Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

Analyst-ratings-2-1
How Is BioMarin Pharmaceuticals Positioned after 1H17?

About 77.2% of analysts tracking BioMarin Pharmaceuticals in September 2017 suggested some form of a “buy” rating.

recommendations
Baxter International's 2017 Performance and 2020 Goals

Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts’ estimates for both revenues and earnings per share.

Graph-3-1
Key Growth Drivers for Acadia Pharmaceuticals in 2017

On April 29, 2016, the FDA approved Acadia Pharmaceuticals’ (ACAD) Nuplazid (pimavanserin) as a first therapy for treating patients with Parkinson’s disease (or PD) psychosis.

Chart-01-Val-1
This Could Be Driving Merck's Valuation after 2Q17

Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16.

Analysts-ratings-1
Who's Talking Jazz Now?

In July 2017, Jazz Pharmaceuticals entered into a license agreement with XL-Protein GmbH involving products using XL-Protein’s PASylation technology.

Graph-1-1
Should Investors Be Interested in Acadia Pharmaceuticals in 2017?

Of the nine analysts covering Acadia Pharmaceuticals in September 2017, two rated the stock a “strong buy,” six rated it a “buy,” and one rated it a “hold.”

Graph-14-1
Why Investors Should Pay Attention to Ligand's Pipeline

With Sparsentan, Retrophin and Ligand Pharmaceuticals could become major nephrology players similar to peers such as Amgen (AMGN), AstraZeneca (AZN), and Bristol-Myers Squibb (BMY).

Analysts-Ratings-1
Who's Watching Bioverativ Now?

Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”

recommendations
Can Edwards Lifesciences Maintain Momentum for the Rest of 2017?

Edwards Lifesciences (EW) had tremendous growth in the first half of 2017. The stock has been recovering from the lows in late 2016 and has recently been on a bullish trend.

Chart-01-EPS-2-1
What Drives AstraZeneca’s Valuation after Its 2Q17 Earnings?

AstraZeneca’s (AZN) stock value has fallen ~11.9% over the last 12 months. Wall Street analysts estimate that the stock has the potential to return ~16.6% over the next 12 months.

recommendations
Boston Scientific: Its Plan to Accelerate and Sustain Growth

Wall Street analysts’ lowest one-year target price for Boston Scientific (BSX) stock is $24, representing a -11.4% maximum downside risk potential for the next year.

Graph-11-3-1
Ligand Pharmaceuticals’ Key Long-Term Growth Drivers

Royalties paid to Ligand Pharmaceuticals (LGND) based on the sales of Amgen’s (AMGN) Kyprolis are a major revenue driver for the company. In 2Q17, LGND earned royalties of ~$222 million on Kyprolis’ sales.

X

Please select a profession that best describes you: